Latest China Biologic Products (CBPO) Headlines
Post# of 46
China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2013
PR Newswire - 2 hrs 3 mins ago
China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its financial results for the fourth quarter and fiscal year 2013.
China Biologic Products to Report Fourth Quarter and Fiscal Year 2013 Financial Results
PR Newswire - Tue Mar 04, 5:00AM CST
China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release fourth quarter and fiscal year 2013 financial results on Wednesday, March 12, 2014 after the market closes.
China Biologic Products reports repurchase of 2.5m shares of common stock
M2 - Mon Mar 03, 6:28AM CST
Biopharmaceutical company China Biologic Products (NASDAQ:CBPO) said on Monday that it has repurchased 2.5m common shares at USD28.00 per share for an aggregate of USD70m .
China Biologic Completes Stock Repurchase Transaction
PR Newswire - Mon Mar 03, 5:00AM CST
China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company has completed its repurchase of 2.5 million shares of common stock for a total consideration of $70 million. This transaction was originally announced in the Company's 8-K SEC filing on January 28, 2014.
Concise Analysis of the International Intravenous Immunoglobulin (IVIg) Market
M2 - Tue Feb 25, 4:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/m8bpfg/intravenous) has announced the addition of the "Concise Analysis of the International Intravenous Immunoglobulin (IVIg) Market" report to their offering. This report analyzes the worldwide markets for Intravenous Immunoglobulin (IVIg) in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 27 companies including many key and niche players such as: - Baxter International Inc. - Beijing Tiantan Biological Products Co. Ltd. - Bharat Serums and Vaccines Ltd. - Biotest AG - China Biologic Products Inc. - Guizhou Taibang Biological Products Co. Ltd. - CSL Limited - CSL Behring - Grifols S.A - Huanlan Biological Engineering Inc. - Kedrion S.p.A. - LFB Group - Octapharma AG - OMRIX Biopharmaceuticals Ltd. - Shanghai RAAS Blood Products Co. Ltd. - Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Plasma Proteins - An Overview 3. Immunoglobulins - An Overview 4. Therapy Overview 5. Regulatory Approvals 6. Product Innovations/Introductions 7. Recent Industry Activity 8. Focus On Select Players 9. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Rest Of World IV. Competitive Landscape Total Companies Profiled: 27 (including Divisions/Subsidiaries - 34) - The United States (9) - Canada (2) - Japan (2) - Europe (9) - France (2) - Germany (1) - The United Kingdom (1) - Italy (1) - Spain (1) - Rest of Europe (3) - Asia-Pacific (Excluding Japan) (11) - Middle-East (1) For more information visit http://www.researchandmarkets.com/research/m8...ntravenous
3 Humongous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Feb 22, 7:25AM CST
Champions weren't just basking in glory at the Sochi Winter Olympic games this week. The world of health care produced quite a few stocks deserving gold medals in their own way. Breaking news about a big acquisition propelled one of our humongous...
3 Stocks Near 52-Week Highs Worth Selling
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 20, 3:25PM CST
Feel free to log our early-2014 "correction" as a distant memory, because the broad-based S&P 500 is once again within striking distance of another all-time closing high. For skeptics like me, that's an opportunity to see whether companies have...
Nasdaq stocks posting largest percentage increases
AP - Wed Feb 19, 5:13PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Global Plasma Market 2012-2016 with Baxter International Inc., CSL Behring LLC, Grifols S.A., and Octapharma AG Dominating
M2 - Tue Feb 04, 9:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/lqj4jb/global_plasma) has announced the addition of the "Global Plasma Market 2012-2016" report to their offering. This report forecasts the Global Plasma market to grow at a CAGR of 10.31 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increase in the aging population. The Global Plasma market has also been witnessing the trend of increasing market consolidation. However, stringent regulations could pose a challenge to the growth of this market. Key vendors dominating this space CSL Behring LLC, Baxter International Inc., Grifols S.A., and Octapharma AG Other vendors mentioned in the report are Kedrion S.p.A., Biotest AG, Sanguine Corp., Cangene bioPharma Inc., Haemacure Corp., Kamada Inc., Omrix Biopharmaceuticals Inc., Vivostat A/S, Pfizer Inc., AstraZeneca plc, Takeda Pharmaceutical Inc., Novo Nordisk A/S, sanofi S.A., China Biologic Products Inc., Beijing Tiantan Biological Products Co. Ltd., Bharat Serums and Vaccines Ltd., and LFB Group. This report Global Plasma Market 2012-2016 is based on an in-depth analysis covering the Americas, the EMEA region, and the APAC region. The report aims to aid decision makers' understanding of the present and future landscape of the market. Commenting on the report, an analyst from the Healthcare team said: 'Over the years, the Global Plasma market has been witnessing significant consolidation and as a result the positions of the leading players have shifted dramatically over the past decade. This trend is expected to continue during the forecast period as vendors attempt to strengthen or hold their market position. Market consolidation has resulted in stronger competitors that are better able to compete as sole-source vendors to end-users. For instance, Australia-based CSL Behring has become one of the world's leading fractionators through a series of acquisitions including its 2000 buyout of ZLB Behring and 2004 purchase of Aventis Behring. Grifols acquisition of Talecris Biotherapeutics has further consolidated the industry.' For more information visit http://www.researchandmarkets.com/research/lq...bal_plasma About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H2 2013 Research Report
M2 - Thu Jan 23, 8:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/6c4qdd/fibrinogen) has announced the addition of the "Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H2 2013" report to their offering. 'Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Fibrinogen Deficiency (Factor I Deficiency), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fibrinogen Deficiency (Factor I Deficiency). Scope - A snapshot of the global therapeutic scenario for Fibrinogen Deficiency (Factor I Deficiency). - A review of the Fibrinogen Deficiency (Factor I Deficiency) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Fibrinogen Deficiency (Factor I Deficiency) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Fibrinogen Deficiency (Factor I Deficiency). - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Fibrinogen Deficiency (Factor I Deficiency) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Biotest AG Pharming Group N.V. Octapharma AG LFB S.A. China Biologic Products, Inc. For more information visit http://www.researchandmarkets.com/research/6c4qdd/fibrinogen About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
China Blood Product Market Analysis & 2015 Forecasts in New Research Report at ChinaMarketResearchReports.com
PRWeb - Mon Dec 30, 8:32PM CST
Plasma is a key raw material of the blood product industry. In August 2011, China shut down 16 plasma stations in Guizhou, resulting in a decrease of 15% in the plasma volume of the year. However, due to the implementation of favorable policies, widening gap between supply and demand, rising product prices and other factors, more than 150 plasma stations in China produced about 3,600 tons of plasma in 2012, up 14.2% year on year. From 2012 to mid-2013, new plasma stations of some Chinese enterprises have started plasma collection or obtained plasma collection permits, such as Yuechi plasma station of Jiangxi Boya Bio-Pharmaceutical, Changyuan plasma station of Hualan Bio, and Caoxian plasma station of China Biologic Products. It's expected that China's plasma supply tension will be further eased after 2013.
Is This the Most Undervalued Biotech of 2013?
Keith Speights, The Motley Fool - Motley Fool - Sun Dec 15, 4:15PM CST
If you were looking for a hot sector to buy at the beginning of 2013, biotech was it. The iShares Nasdaq Biotechnology ETF has soared more than 56% this year with only a few weeks to go. With biotech sizzling, you might think it would be hard to...
China Biologic Products, Inc. SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of China Biologic Products, Inc.
Business Wire - Wed Nov 13, 1:50PM CST
Levi & Korsinsky, LLP is investigating China Biologic Products, Inc. (NasdaqGS: CBPO) in connection with possible claims of breaches of fiduciary duty.
China Biologic Reports Financial Results for the Third Quarter and First Nine Months of 2013
PR Newswire - Tue Nov 05, 4:00PM CST
China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its unaudited financial results for the third quarter of 2013.
Investors' 3 Most Loved Biotech Stocks
Sean Williams, The Motley Fool - Motley Fool - Tue Oct 29, 11:20AM CDT
As I said yesterday, the biotech sector can be like a roulette wheel at times. When you choose correctly, it can turn into a double, triple, or even 10-bagger; and when you miss, you could very well lose 80%, 90%, or practically all of your...
China Biologic Products to Report Third Quarter 2013 Financial Results
PR Newswire - Mon Oct 28, 3:01PM CDT
China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release third quarter 2013 financial results on Tuesday, November 5, 2013 after the market closes.
Hemophilia B - Pipeline Review, H2 2013
M2 - Thu Sep 05, 8:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k8zp3t/hemophilia_b) has announced the addition of the "Hemophilia B - Pipeline Review, H2 2013" report to their offering. 'Hemophilia B - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hemophilia B, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemophilia B. Scope - A snapshot of the global therapeutic scenario for Hemophilia B. - A review of the Hemophilia B products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hemophilia B pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Hemophilia B. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Hemophilia B pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Baxter International Inc. Biogen Idec Inc. AstraZeneca PLC Cangene Corporation Sangamo BioSciences, Inc. Novo Nordisk A/S Pfizer Inc. PROLOR Biotech, Inc. ReGenX Biosciences, LLC CSL Limited Amarna Therapeutics B.V. Asklepios BioPharmaceutical, Inc. China Biologic Products, Inc. LFB Biotechnologies, S.A.S.U. PolyTherics Limited For more information visit http://www.researchandmarkets.com/research/k8...mophilia_b About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Intravenous Immunoglobulin (IVIg) - Global Strategic Business Report: 2013 Profiles 27 Players including Key and Niche Players
M2 - Tue Sep 03, 9:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hjhhwq/intravenous#summary) has announced the addition of the "Intravenous Immunoglobulin (IVIg) - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Intravenous Immunoglobulin (IVIg) in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 27 companies including many key and niche players such as: - Baxter International Inc. - Beijing Tiantan Biological Products Co. Ltd. - Bharat Serums and Vaccines Ltd. - Biotest AG - China Biologic Products Inc. - Guizhou Taibang Biological Products Co. Ltd. - CSL Limited - CSL Behring - Grifols S.A - Huanlan Biological Engineering Inc. - Kedrion S.p.A. - LFB Group - Octapharma AG - OMRIX Biopharmaceuticals Ltd. - Shanghai RAAS Blood Products Co. Ltd. - Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered: Normal 0 false false false MicrosoftInternetExplorer4 I. Introduction, Methodology & Product Definitions Ii. Executive Summary 1. Industry Overview 2. Plasma Proteins - An Overview 3. Immunoglobulins - An Overview 4. Therapy Overview 5. Regulatory Approvals 6. Product Innovations/Introductions 7. Recent Industry Activity 8. Focus On Select Players 9. Global Market Perspective Iii. Market Iv. Competitive Landscape For more information visit http://www.researchandmarkets.com/research/hj...us#summary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
China Biologic to Participate in Upcoming Investor Conferences
PR Newswire - Thu Aug 29, 7:00AM CDT
China Biologic Products, Inc. (Nasdaq: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, is scheduled to participate in the upcoming conferences: